$324 Million is the total value of Sarissa Capital Management LP's 9 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 12.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BIIB | BIOGEN INC | $120,193,000 | +15.4% | 383,858 | 0.0% | 37.10% | +6.7% | |
| BIOVERATIV INC | $66,486,000 | -5.2% | 1,165,000 | 0.0% | 20.52% | -12.3% | ||
| MDCO | MEDICINES CO | $64,894,000 | -2.6% | 1,752,000 | 0.0% | 20.03% | -9.9% | |
| INVA | Buy | INNOVIVA INC | $50,841,000 | +13.8% | 3,600,705 | +3.2% | 15.69% | +5.2% |
| ACHN | New | ACHILLION PHARMACEUTICALS INC | $9,594,000 | – | 2,136,800 | +100.0% | 2.96% | – |
| NVLNF | NOVELION THERAPEUTICS INC | $7,205,000 | -23.8% | 1,025,000 | 0.0% | 2.22% | -29.6% | |
| APRI | APRICUS BIOSCIENCES INC | $2,475,000 | +51.3% | 1,447,906 | 0.0% | 0.76% | +39.9% | |
| ADXS | ADVAXIS INC | $1,417,000 | -35.6% | 339,180 | 0.0% | 0.44% | -40.5% | |
| ABBV | ABBVIE INC. | $888,000 | +22.5% | 10,000 | 0.0% | 0.27% | +13.2% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC. | 32 | Q3 2023 | 37.1% |
| INNOVIVA INC. | 29 | Q3 2023 | 19.5% |
| IRONWOOD PHARMACEUTICALS INC. | 24 | Q3 2023 | 24.2% |
| ABBVIE INC. | 23 | Q2 2020 | 24.4% |
| MEDICINES CO. | 20 | Q4 2019 | 33.9% |
| MERSANA THERAPEUTICS INC. | 19 | Q3 2023 | 7.9% |
| ALKERMES PLC | 16 | Q3 2023 | 43.7% |
| INTERCEPT PHARMACEUTICALS INC. | 15 | Q2 2021 | 10.7% |
| BIOCRYST PHARMACEUTICALS INC | 14 | Q3 2023 | 7.4% |
| VIVUS INC | 14 | Q1 2017 | 8.8% |
View Sarissa Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Alkermes plc. | August 24, 2023 | 8,323,400 | 5.0% |
| Innoviva, Inc. | May 15, 2023 | 6,904,000 | 10.5% |
| IRONWOOD PHARMACEUTICALS INC | March 01, 2021 | 14,890,000 | 9.3% |
| Iterum Therapeutics plcSold out | February 12, 2021 | 0 | 0.0% |
| BIOCRYST PHARMACEUTICALS INC | January 25, 2021 | 8,844,000 | 5.0% |
| Mersana Therapeutics, Inc. | January 25, 2021 | 3,770,000 | 5.5% |
| MEDICINES CO /DESold out | January 07, 2020 | 0 | 0.0% |
| Regulus Therapeutics Inc. | January 03, 2020 | 7,935,322 | 29.4% |
| NOVELION THERAPEUTICS INC. | November 09, 2018 | 909,296 | 4.6% |
| APRICUS BIOSCIENCES, INC. | September 05, 2018 | 1,152,455 | 4.8% |
View Sarissa Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-19 |
| 13F-HR | 2024-02-14 |
| 4 | 2023-12-19 |
| SC 13D/A | 2023-12-05 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-19 |
| SC 13D/A | 2023-09-05 |
| SC 13D/A | 2023-08-24 |
| 13F-HR | 2023-08-14 |
| DFAN14A | 2023-06-28 |
View Sarissa Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.